Inventor · disambiguated record
Bireshwar Dasgupta
Also filed as: DASGUPTA BIRESHWAR
16 granted patents·6 pending applications·31 citations·filing 1999–2024
90Inventor score
Top patents by PatentIndex Score
22 records- 0188US10669272B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jun 2, 2020·4 cites·13 claims
- 0280US2024400563A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 0377US6888004B2Imidazolyl derivatives as corticotropin releasing factor inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2002·Granted May 3, 2005·7 cites·23 claims
- 0474US2023151007A1Substituted pyridopyrimidinonyl compounds useful as t cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 0573US11166959B2Isofuranone compounds useful as HPK1 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Nov 9, 2021·1 cites·15 claims
- 0671US6939968B2Atropisomers of 3-substituted-4-arylquinolin-2-one derivativesBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Sep 6, 2005·6 cites·20 claims
- 0770US7238699B2Imidazolyl derivatives as corticotropin releasing factor inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jul 3, 2007·3 cites·18 claims
- 0867US11713316B2Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Aug 1, 2023·0 cites·11 claims
- 0967US7211669B2Imidazolyl derivatives as corticotropin releasing factor inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted May 1, 2007·2 cites·6 claims
- 1066US11584747B2Substituted pyridopyrimidinonyl compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 21, 2023·0 cites·33 claims
- 1166US9273058B2Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 1, 2016·1 cites·14 claims
- 1265US9932320B2Quinoline-based kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Apr 3, 2018·1 cites·10 claims
- 1365US6239146B1Neurotrophic difluoroamide agentsBRISTOL MYERS SQUIBB CO·Filed 2000·Granted May 29, 2001·2 cites·13 claims
- 1461US10954238B1Substituted naphthyridinone compounds useful as T cell activatorsBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Mar 23, 2021·0 cites·11 claims
- 1555US2024108654A1Combination of a t cell therapy and a dgk inhibitorJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1653US9598423B2Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 21, 2017·0 cites·13 claims
- 1751US2023089255A1Combinations of dgk inhibitors and checkpoint antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1846US9737542B2Pyrrolotriazine kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Aug 22, 2017·0 cites·7 claims
- 1943US6096762ANeurotrophic difluoroamide agentsBRISTOL MYERS SQUIBB CO·Filed 1999·Granted Aug 1, 2000·4 cites·11 claims
- 2042US2016122358A1Novel substituted pyrazolo-piperazines as casein kinase 1 d/e inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Application pending·0 cites
- 2135US10035777B2Heterocyclic kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jul 31, 2018·0 cites·12 claims
- 2235US2017239249A1Quinazoline-based kinase inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bireshwar Dasgupta files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →